Abstract
The ubiquitously expressed nitric oxide (NO) receptor soluble guanylate cyclase (sGC) plays a key role in signal transduction. Binding of NO to the N-terminal prosthetic heme moiety of sGC results in ∼200-fold activation of the enzyme and an increased conversion of GTP into the second messenger cGMP. sGC exists as a heterodimer the dimerization of which is mediated mainly by the central region of the enzyme. In the present work, we constructed deletion mutants within the predicted dimerization region of the sGC α1- and β1-subunit to precisely map the sequence segments crucial for subunit dimerization. To track mutation-induced alterations of sGC dimerization, we used a bimolecular fluorescence complementation approach that allows visualizing sGC heterodimerization in a noninvasive manner in living cells. Our study suggests that segments spanning amino acids α1363–372, α1403–422, α1440–459, β1212–222, β1304–333, β1344–363, and β1381–400 within the predicted dimerization region are involved in the process of heterodimerization and therefore in the expression of functional sGC.
Footnotes
-
P.M.S. is the recipient of an Alexander-von-Humboldt Lynen fellowship.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.036368.
-
ABBREVIATIONS: sGC, soluble guanylate cyclase; H-NOX, N-terminal NO-sensing heme domain; BiFC, bimolecular fluorescence complementation; BAY 58-2667, 4-[((4-carboxybutyl){2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl[benzoic]acid; BAY 41-2272, 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine; DEA/NO, 2-(N,N-diethylamino)-diazenolate-2-oxide; ODQ, 1H-(1,2,4)-oxadiazole-(4,3-a)-quinoxalin-1-one; YFP, yellow fluorescent protein; YC, C-terminal fragment of YFP; YN, N-terminal fragment of YFP; WT, wild-type; NBS, N-terminal binding site; CBS, C-terminal binding site.
- Received March 26, 2007.
- Accepted August 9, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|